<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="joor13971" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oral Rehabil</journal-id><journal-id journal-id-type="iso-abbrev">J Oral Rehabil</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2842</journal-id><journal-id journal-id-type="publisher-id">JOOR</journal-id><journal-title-group><journal-title>Journal of Oral Rehabilitation</journal-title></journal-title-group><issn pub-type="ppub">0305-182X</issn><issn pub-type="epub">1365-2842</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40183199</article-id><article-id pub-id-type="pmc">PMC12102682</article-id>
<article-id pub-id-type="doi">10.1111/joor.13971</article-id><article-id pub-id-type="publisher-id">JOOR13971</article-id><article-id pub-id-type="other">JOR-25-0026.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Beyond Depression: The Role of Antidepressants in Managing Chronic Temporomandibular Disorders. A Systematic Review</article-title></title-group><contrib-group><contrib id="joor13971-cr-0001" contrib-type="author"><name><surname>Dei</surname><given-names>Takara</given-names></name><xref rid="joor13971-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="joor13971-cr-0002" contrib-type="author"><name><surname>Galloway</surname><given-names>Kennedy</given-names></name><xref rid="joor13971-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="joor13971-cr-0003" contrib-type="author"><name><surname>Fagundes</surname><given-names>Nathalia Carolina Fernandes</given-names></name><xref rid="joor13971-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="joor13971-cr-0004" contrib-type="author"><name><surname>Kung</surname><given-names>Janice Y.</given-names></name><xref rid="joor13971-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="joor13971-cr-0005" contrib-type="author"><name><surname>Beahm</surname><given-names>Nathan P.</given-names></name><xref rid="joor13971-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="joor13971-cr-0006" contrib-type="author" corresp="yes"><name><surname>Friesen</surname><given-names>Reid</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6393-3559</contrib-id><xref rid="joor13971-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>rtfriese@ualberta.ca</email></address></contrib></contrib-group><aff id="joor13971-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Faculty of Pharmacy and Pharmaceutical Sciences</named-content>
<institution>University of Alberta</institution>
<city>Edmonton</city>
<named-content content-type="country-part">Alberta</named-content>
<country country="CA">Canada</country>
</aff><aff id="joor13971-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Physiology, Faculty of Medicine and Dentistry, College of Health Sciences</named-content>
<institution>University of Alberta</institution>
<city>Edmonton</city>
<country country="CA">Canada</country>
</aff><aff id="joor13971-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Mike Petryk School of Dentistry, Faculty of Medicine and Dentistry, College of Health Sciences</named-content>
<institution>University of Alberta</institution>
<city>Edmonton</city>
<country country="CA">Canada</country>
</aff><aff id="joor13971-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Geoffrey and Robyn Sperber Health Sciences Library</named-content>
<institution>University of Alberta</institution>
<city>Edmonton</city>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Reid Friesen (<email>rtfriese@ualberta.ca</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>52</volume><issue seq="230">6</issue><issue-id pub-id-type="doi">10.1111/joor.v52.6</issue-id><fpage>923</fpage><lpage>936</lpage><history>
<date date-type="rev-recd"><day>18</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>09</day><month>1</month><year>2025</year></date>
<date date-type="accepted"><day>26</day><month>3</month><year>2025</year></date>
</history><permissions><!--Copyright &#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Oral Rehabilitation</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JOOR-52-923.pdf"/><abstract><title>ABSTRACT</title><sec id="joor13971-sec-0001"><title>Background</title><p>Chronic temporomandibular disorder (TMD) pain significantly impairs quality of life and lacks universally effective treatments. Antidepressants, traditionally used for mood disorders, have shown potential in managing chronic pain conditions. This systematic review evaluates the efficacy and safety of antidepressants for chronic TMD pain management.</p></sec><sec id="joor13971-sec-0002"><title>Methods</title><p>Eligibility criteria: Included randomised controlled trials (RCTs) assessing antidepressants for chronic TMD pain in adults, reporting pain reduction or functional improvement as outcomes. <italic toggle="no">Information sources</italic>: Searches were conducted in MEDLINE, Embase, CINAHL, Scopus, Web of Science, and Cochrane Library through April 2024. <italic toggle="no">Risk of bias</italic>: The Cochrane Risk of Bias 2 tool was used to assess study quality. <italic toggle="no">Synthesis of results</italic>: Narrative synthesis was performed due to heterogeneity in interventions and outcomes.</p></sec><sec id="joor13971-sec-0003"><title>Results</title><p>Included studies: Seven RCTs with sample sizes ranging from 12 to 80 participants. Studies evaluated various antidepressants, including amitriptyline, duloxetine, nortriptyline, and citalopram, alone or combined with non&#x02010;pharmacological treatments. Synthesis of results: Amitriptyline and duloxetine demonstrated significant reductions in pain intensity when used in combination therapies. Functional improvements, such as increased mouth opening, were observed in some studies. Side effects, particularly with duloxetine, were more frequent than with placebo. Variability in study designs, populations, and outcome measures limited comparability. Small sample sizes, short follow&#x02010;up durations, and heterogeneity in interventions and outcomes reduced the strength of evidence.</p></sec><sec id="joor13971-sec-0004"><title>Conclusion</title><p>Antidepressants, particularly when combined with non&#x02010;pharmacological treatments, may enhance pain relief and functional outcomes for chronic TMD pain. However, high&#x02010;quality, long&#x02010;term studies are needed.</p></sec></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="joor13971-blkfxd-0001"><graphic xlink:href="JOOR-52-923-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="joor13971-kwd-0001">antidepressants</kwd><kwd id="joor13971-kwd-0002">orofacial pain</kwd><kwd id="joor13971-kwd-0003">temporomandibular disorders</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="14"/><word-count count="7700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:24.05.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="joor13971-body-0001"><sec sec-type="background" id="joor13971-sec-0005"><label>1</label><title>Background</title><p>Temporomandibular disorders (TMDs) represent a group of musculoskeletal conditions that affect 5%&#x02013;12% of the population and are a primary cause of orofacial pain [<xref rid="joor13971-bib-0001" ref-type="bibr">1</xref>, <xref rid="joor13971-bib-0002" ref-type="bibr">2</xref>]. TMD&#x02010;related pain is commonly classified into two primary subtypes based on the source of pain: arthrogenous and myogenous pain. Arthrogenous pain originates from the temporomandibular joint (TMJ) and is typically linked to structural abnormalities, degenerative changes, or inflammation within the joint. Patients with arthrogenous pain often present with joint tenderness, crepitus, and discomfort that worsens with jaw movement. Myogenous pain, in contrast, originates from the masticatory muscles and is typically described as diffuse, dull, and aching. It is often accompanied by muscle tenderness, fatigue, and stiffness. This type of pain frequently coexists with other chronic pain conditions and is significantly influenced by psychosocial factors such as stress and anxiety [<xref rid="joor13971-bib-0003" ref-type="bibr">3</xref>].</p><p>TMD pain is classified as acute or chronic. Acute pain typically arises suddenly due to trauma, overuse, or inflammation and resolves within 3&#x02009;months with appropriate management. In contrast, chronic TMD pain persists beyond 3&#x02009;months and is multifactorial, involving peripheral and central mechanisms, psychological factors, and functional impairments [<xref rid="joor13971-bib-0004" ref-type="bibr">4</xref>]. It significantly impacts quality of life, affecting physical function, psychological well&#x02010;being, and social participation.</p><p>Unlike acute pain, chronic TMD pain often extends beyond localised structural abnormalities, involving more complex pain&#x02010;processing mechanisms. Nociplastic pain, a term introduced by the International Association for the Study of Pain (IASP) in 2016, describes pain arising from altered central nervous system processing rather than tissue injury or inflammation [<xref rid="joor13971-bib-0005" ref-type="bibr">5</xref>]. Many cases of chronic TMD pain exhibit nociplastic characteristics, such as widespread, fluctuating pain with central sensitisation features&#x02014;including fatigue, sleep disturbances, mood disorders, and multisensory hypersensitivity [<xref rid="joor13971-bib-0005" ref-type="bibr">5</xref>, <xref rid="joor13971-bib-0006" ref-type="bibr">6</xref>]. This overlap highlights the need for management strategies that address both peripheral and central pain mechanisms.</p><p>Chronic TMD pain is typically managed using a conservative approach initially, with more invasive treatments considered based on the patient's response [<xref rid="joor13971-bib-0004" ref-type="bibr">4</xref>]. Conservative therapies include physiotherapy, psychotherapy, pharmacotherapy, and oral appliance therapy, all of which aim to reduce pain and improve function with varying degrees of success [<xref rid="joor13971-bib-0007" ref-type="bibr">7</xref>]. Oral appliances, in particular, are custom&#x02010;fitted devices worn intraorally&#x02014;often during sleep&#x02014;to help decrease jaw muscle activity, alleviate pain, and enhance jaw function. When conservative treatments prove insufficient, more invasive interventions such as trigger point injections, arthroscopy, or open joint surgery may be considered [<xref rid="joor13971-bib-0007" ref-type="bibr">7</xref>, <xref rid="joor13971-bib-0008" ref-type="bibr">8</xref>]. However, no single treatment has demonstrated universal efficacy, leading to ongoing exploration of alternative pharmacological options, including antidepressants.</p><p>Given the complex and multifactorial nature of chronic TMD pain, pharmacological treatments that target central pain processing have been considered as treatment options. Antidepressants, traditionally used for mood disorders, have demonstrated efficacy in managing various chronic pain conditions [<xref rid="joor13971-bib-0009" ref-type="bibr">9</xref>]. Duloxetine, a serotonin&#x02010;norepinephrine reuptake inhibitor (SNRI), has been studied for its analgesic effects in fibromyalgia, diabetic neuropathy, and chronic osteoarthritis pain [<xref rid="joor13971-bib-0010" ref-type="bibr">10</xref>]. Likewise, tricyclic antidepressants (TCAs), including amitriptyline, have shown effectiveness in neuropathic pain and other chronic pain conditions, supporting their potential application in TMD pain treatment [<xref rid="joor13971-bib-0011" ref-type="bibr">11</xref>].</p><p>Since some cases of chronic TMD pain exhibit features of nociplastic pain, centrally acting agents like antidepressants may provide therapeutic benefits that extend beyond conventional treatments. By modulating neurotransmitters like serotonin and norepinephrine, these medications not only influence pain perception but may also help address associated symptoms such as mood disturbances and sleep disruptions. Given their dual impact on pain processing and psychological comorbidities, antidepressants represent a potential option for patients with chronic TMD pain who do not achieve sufficient relief with standard conservative approaches. Table&#x000a0;<xref rid="joor13971-tbl-0001" ref-type="table">1</xref> summarises commonly prescribed antidepressants, their indications, and their mechanisms of action.</p><table-wrap position="float" id="joor13971-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Common antidepressants and their associated indication and mechanism of action.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Drug</th><th align="center" valign="bottom" rowspan="1" colspan="1">Indications</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mechanism of action</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Tricyclic Antidepressants (TCAs) (e.g., amitriptyline, nortriptyline, desipramine)</td><td align="center" valign="top" rowspan="1" colspan="1">FDA&#x02010;approved for the treatment of depression; also prescribed off&#x02010;label for chronic pain, insomnia, obsessive&#x02010;compulsive disorder (OCD), migraine prophylaxis, and anxiety</td><td align="center" valign="top" rowspan="1" colspan="1">Increases the concentration of norepinephrine and serotonin in the brain, enhancing mood and regulating depression. This drug may also block pain signals in the spinal cord or inhibit peripheral pain signals, providing relief for chronic pain [<xref rid="joor13971-bib-0012" ref-type="bibr">12</xref>, <xref rid="joor13971-bib-0013" ref-type="bibr">13</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g., fluoxetine, sertraline, citalopram, escitalopram, paroxetine, fluvoxamine)</td><td align="center" valign="top" rowspan="1" colspan="1">FDA&#x02010;approved for depression, OCD, bulimia nervosa, panic disorder, PTSD, social anxiety disorder, premenstrual dysphoric disorder, and generalised anxiety disorder. Off&#x02010;label uses include binge eating disorder, chronic pelvic pain, rheumatoid arthritis, and premature ejaculation</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibits the reuptake of serotonin in the brain, increasing serotonin levels. The precise mechanism for pain relief remains unclear [<xref rid="joor13971-bib-0014" ref-type="bibr">14</xref>, <xref rid="joor13971-bib-0015" ref-type="bibr">15</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serotonin&#x02010;Norepinephrine Reuptake Inhibitors (SNRIs) (e.g., venlafaxine, desvenlafaxine, duloxetine, levomilnacipran, milnacipran)</td><td align="center" valign="top" rowspan="1" colspan="1">FDA&#x02010;approved for depression, anxiety, ADHD, chronic pain, diabetic peripheral neuropathic pain, bipolar disorder, fibromyalgia, and chronic musculoskeletal pain</td><td align="center" valign="top" rowspan="1" colspan="1">Enhances serotonergic and noradrenergic activity in the CNS. The precise pain relief mechanism is partially understood but thought to involve amplified central pain modulation [<xref rid="joor13971-bib-0016" ref-type="bibr">16</xref>, <xref rid="joor13971-bib-0017" ref-type="bibr">17</xref>, <xref rid="joor13971-bib-0018" ref-type="bibr">18</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Norepinephrine&#x02010;Dopamine Reuptake Inhibitors (NDRIs) (e.g., bupropion)</td><td align="center" valign="top" rowspan="1" colspan="1">FDA&#x02010;approved for major depressive disorder, seasonal affective disorder, and smoking cessation. Off&#x02010;label uses include ADHD, bipolar disorder, and SSRI&#x02010;induced sexual dysfunction</td><td align="center" valign="top" rowspan="1" colspan="1">Treats depression by inhibiting the reuptake of norepinephrine and dopamine, enhancing their levels in the brain, and antagonising nicotinic acetylcholine receptors, which improves mood and motivation without significant serotonergic effects [<xref rid="joor13971-bib-0019" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Monoamine Oxidase Inhibitors (MAOIs) (e.g., phenelzine, tranylcypromine, isocarboxazid, selegiline)</td><td align="center" valign="top" rowspan="1" colspan="1">FDA&#x02010;approved for major depressive disorder and Parkinsonian syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">Blocks the monoamine oxidase enzyme, increasing levels of serotonin, norepinephrine, dopamine, and epinephrine in the CNS, thereby alleviating depressive symptoms [<xref rid="joor13971-bib-0020" ref-type="bibr">20</xref>, <xref rid="joor13971-bib-0021" ref-type="bibr">21</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serotonin Antagonists and Reuptake Inhibitors (SARIs) (e.g., trazodone, nefazodone)</td><td align="center" valign="top" rowspan="1" colspan="1">FDA&#x02010;approved for major depressive disorder. Off&#x02010;label uses include insomnia (for sleep onset and maintenance) and dementia&#x02010;associated agitation</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibiting serotonin reuptake and acting as a serotonin receptor antagonist, primarily at 5&#x02010;HT2A receptors, while also having sedative effects due to its antihistaminergic and alpha&#x02010;adrenergic blocking properties&#x000a0;[<xref rid="joor13971-bib-0020" ref-type="bibr">20</xref>, <xref rid="joor13971-bib-0022" ref-type="bibr">22</xref>]</td></tr></tbody></table></table-wrap><p>This systematic review aims to explore the role of antidepressants in managing TMD pain, addressing a critical gap in understanding their efficacy and clinical application for this unique pain condition.</p></sec><sec sec-type="methods" id="joor13971-sec-0006"><label>2</label><title>Methods</title><sec id="joor13971-sec-0007"><label>2.1</label><title>Protocol and Registration</title><p>The reporting of this systematic review was guided by the standards of the Preferred Reporting Items for Systematic Review and Meta&#x02010;Analysis (PRISMA) Statement [<xref rid="joor13971-bib-0023" ref-type="bibr">23</xref>]. The review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42024524578. The protocol can be accessed through <ext-link xlink:href="https://www.crd.york.ac.uk/prospero/" ext-link-type="uri">https://www.crd.york.ac.uk/prospero/</ext-link>. No external funding was provided for this study.</p></sec><sec id="joor13971-sec-0008"><label>2.2</label><title>Eligibility Criteria</title><p>The scope of this systematic review was defined using the PICO framework, which also guided the definition of the eligibility criteria:
<list list-type="bullet" id="joor13971-list-0001"><list-item id="joor13971-li-0001"><p>Population (P): Adults diagnosed with chronic TMD pain, including individuals with myofascial pain, arthralgia, or other TMD&#x02010;related chronic pain conditions.</p></list-item><list-item id="joor13971-li-0002"><p>Intervention (I): The use of antidepressants. Studies where antidepressants were combined with non&#x02010;pharmacological treatments were also included.</p></list-item><list-item id="joor13971-li-0003"><p>Comparator (C): Any treatment that does not include antidepressants, including placebo, non&#x02010;systemic pharmacological treatments (e.g., NSAIDs, muscle relaxants), non&#x02010;pharmacological interventions (e.g., oral appliances, trigger point injections, physiotherapy, arthrocentesis with or without additional medications such as corticosteroids), or standard care without antidepressants.</p></list-item><list-item id="joor13971-li-0004"><p>Outcome (O): Primary outcomes included pain reduction (e.g., measured by VAS, NRS) and functional improvement (e.g., mouth opening, quality of life). Secondary outcomes included adverse effects and improvement in associated symptoms, such as depression or anxiety.</p></list-item></list>
</p><p>Studies were included if they examined the use of antidepressants for managing chronic TMD pain, enrolled adult participants (&#x02265;&#x02009;18&#x02009;years) diagnosed with chronic TMD&#x02014;defined as pain persisting for at least 3&#x02009;months&#x02014;based on the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) with a diagnosis of myalgia or arthralgia, and utilised a randomised controlled trial (RCT) design; reported primary outcomes related to pain reduction, quality of life, or functional improvement; published in peer&#x02010;reviewed journals and available in the English language.</p><p>Studies were excluded if they met the following criteria: non&#x02010;randomised studies, observational studies, case reports, reviews, and editorials; studies focused on other types of orofacial pain (non&#x02010;TMD); studies involving participants with severe psychiatric disorders unrelated to TMD.</p></sec><sec id="joor13971-sec-0009"><label>2.3</label><title>Search Strategy</title><p>A comprehensive search strategy was developed and executed in collaboration with the medical librarian (JYK) to identify relevant studies. On 22 April 2024, searches were conducted across multiple electronic databases, including Ovid MEDLINE, Ovid Embase, CINAHL, Scopus, Web of Science Core Collection, and the Cochrane Library (via Wiley). Relevant keywords and controlled vocabulary were carefully selected to capture all literature about the use of antidepressants in managing chronic TMD. The search was limited to studies published in English. Full search strategies are detailed in the appendices (Table&#x000a0;<xref rid="joor13971-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="joor13971-sec-0010"><label>2.4</label><title>Study Selection</title><p>Covidence (<ext-link xlink:href="http://www.covidence.org" ext-link-type="uri">www.covidence.org</ext-link>), a web&#x02010;based tool for managing systematic reviews, was used to screen and select the studies. The study selection process involved two independent reviewers who screened titles and abstracts of all the unique records after duplicate removal to assess their eligibility based on the predefined inclusion and exclusion criteria. Full&#x02010;text articles were then reviewed in detail to confirm their eligibility. Discrepancies between reviewers (KG and TD) were resolved through discussion or by consulting a third reviewer (RF). Additionally, the bibliographies of included studies were reviewed for any relevant references.</p></sec><sec id="joor13971-sec-0011"><label>2.5</label><title>Data Collection Process</title><p>Data extraction was carried out independently by two reviewers using a standardised form. Extracted data included bibliographic information (e.g., author, year of publication, country), participant demographics (e.g., sample size, age, diagnosis), intervention details (e.g., type of antidepressant, dosage, duration), comparator interventions, and reported outcomes (e.g., pain reduction, quality of life, adverse effects). Any discrepancies in data extraction were resolved through consensus or consultation with a third reviewer. In case of missing data, the corresponding author of the included study was contacted by email for up to three consecutive weeks, in which one contact attempt per week was performed.</p><p>In addition to outcomes, data were extracted on the following variables: participant characteristics (age, gender, diagnostic criteria, and duration of TMD pain), intervention details (type, dosage, and duration of antidepressant treatment), comparator details (placebo or non&#x02010;pharmacological treatments), and study characteristics (design, sample size, and setting). Efforts were made to contact study authors to clarify missing or ambiguous data, though this was not always successful.</p></sec><sec id="joor13971-sec-0012"><label>2.6</label><title>Risk of Bias Assessment and Applicability</title><p>The risk of bias in the included studies was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, which evaluates key domains such as random sequence generation, allocation concealment, blinding of participants and outcome assessors, completeness of outcome data, and selective reporting. Based on these criteria, each study was categorised as low risk of bias, some concerns, or a high risk of bias [<xref rid="joor13971-bib-0024" ref-type="bibr">24</xref>]. Additionally, the applicability of the study findings was assessed to determine the generalisability of the populations, interventions, and outcomes to clinical practice.</p></sec><sec id="joor13971-sec-0013"><label>2.7</label><title>Summary Measures and Data Synthesis</title><p>The data collected was summarised in Table&#x000a0;<xref rid="joor13971-tbl-0002" ref-type="table">2</xref>, and a narrative synthesis was prepared. The feasibility of a quantitative synthesis (i.e., meta&#x02010;analysis) was assessed for the included studies. However, a meta&#x02010;analysis could not be performed due to significant clinical heterogeneity across included studies (i.e., use of different antidepressants between studies) and missing data (i.e., some studies reported their findings in a graphical presentation only). In case of missing data, attempts have been made to contact the corresponding authors, but they were unsuccessful. Clinical heterogeneity across studies, including variations in antidepressant classes, comparator interventions, and outcome measures, was identified during data synthesis. While formal methods such as subgroup analysis or meta&#x02010;regression were not performed due to the limited number of comparable studies, heterogeneity was narratively explored by grouping studies according to antidepressant class and outcome domains. Differences in study design, population characteristics, and intervention protocols were also qualitatively examined to identify potential sources of variability in results.</p><table-wrap position="float" id="joor13971-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Summary of descriptive characteristics of included articles.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Author/year/country/journal</th><th align="center" rowspan="2" valign="bottom" colspan="1">Population studied, sample size, <italic toggle="yes">N</italic>, age range or mean of age</th><th align="center" colspan="4" valign="bottom" rowspan="1">Intervention characteristics</th><th align="center" rowspan="2" valign="bottom" colspan="1">Outcomes in intervention group(s), adverse effects, follow&#x02010;up</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Diagnosis</th><th align="center" valign="bottom" rowspan="1" colspan="1">Intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Comparator</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcome measures</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Rizzatti&#x02010;Barbosa et&#x000a0;al. 2003 [<xref rid="joor13971-bib-0025" ref-type="bibr">25</xref>] Brazil/J Applied Oral Sci</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Population: Female patients with signs and symptoms of chronic TMD. Excluded were pregnant/breastfeeding individuals, those with systemic diseases, and individuals on other medications at the time of the study.</p>
<p>sample size:12</p>
<p>age (range/mean): &#x02265;&#x02009;18&#x02009;years of age</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Chronic TMD&#x02014;not specifically calibrated</td><td align="center" valign="top" rowspan="1" colspan="1">25&#x02009;mg amitriptyline once daily for 14&#x02009;days</td><td align="center" valign="top" rowspan="1" colspan="1">Placebo pill identical in size and appearance to amitriptyline 25&#x02009;mg</td><td align="center" valign="top" rowspan="1" colspan="1">VAS for pain and discomfort</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pain reduction: VAS baseline: 44%; post&#x02010;treatment: 10.14% (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01).</p>
<p>discomfort reduction: baseline: 45.42%; post&#x02010;treatment: 12.33%.</p>
<p>adverse effects: none reported.</p>
<p>follow&#x02010;up: 14&#x02009;days</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alajbeg et&#x000a0;al. 2018 [<xref rid="joor13971-bib-0026" ref-type="bibr">26</xref>] Croatia/Acta Stomatologica Croatica</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Population: Patients with chronic TMD. Excluded: systemic disease, pregnancy, cardiac issues.</p>
<p>Sample size: 13: Group A: 4, Group B: 4, Group C: 5.</p>
<p>Age (range or mean): Group A: 57.2&#x02009;&#x000b1;&#x02009;8.1&#x02009;years; Group B: 46.5&#x02009;&#x000b1;&#x02009;18.1&#x02009;years; Group C: 42.8&#x02009;&#x000b1;&#x02009;12.4&#x02009;years</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">RDC/TMD (Groups I and II)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Group A: Amitriptyline 25&#x02009;mg daily for 12&#x02009;weeks.</p>
<p>Group C: Oral appliance is worn during sleep</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Group B: Placebo pill identical in size and appearance to amitriptyline 25&#x02009;mg</td><td align="center" valign="top" rowspan="1" colspan="1">VAS for pain, OHIP&#x02010;14 for oral health&#x02010;related quality of life, and MCO for maximum comfortable opening</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pain reduction: Significant reductions in VAS in the amitriptyline group (<italic toggle="yes">F</italic>&#x02009;=&#x02009;11.326, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002) and oral appliance (<italic toggle="yes">F</italic>&#x02009;=&#x02009;7.343, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.005).</p>
<p>Quality of Life (OHIP&#x02010;14): Significant improvement in the amitriptyline group only (<italic toggle="yes">F</italic>&#x02009;=&#x02009;4.417, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.036).</p>
<p>Comfortable mouth opening: Significant improvement in the oral appliance group compared to amitriptyline and placebo (<italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p>
<p>Adverse effects: None reported.</p>
<p>Follow&#x02010;Up: 1st, 6th, and 12th week</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Singh et&#x000a0;al. 2018 [<xref rid="joor13971-bib-0010" ref-type="bibr">10</xref>] India/J Maxillofac Oral Surg</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Population: Patients with TMJ pain confirmed by RDC/TMD criteria, pain duration &#x02265;&#x02009;3&#x02009;months. Exclusions: systemic diseases, pregnancy, breastfeeding, allergies.</p>
<p>Sample size: 20 (Group A: 10, Group B: 10).</p>
<p>Age (range or mean): &#x02265;&#x02009;18&#x02009;years</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">TMJ pain confirmed by RDC/TMD criteria, with emphasis on pain of non&#x02010;odontogenic origin and presence of symptoms for at least 3&#x02009;months</td><td align="center" valign="top" rowspan="1" colspan="1">Group B: TMJ arthrocentesis + duloxetine 30&#x02009;mg BID for 12&#x02009;weeks</td><td align="center" valign="top" rowspan="1" colspan="1">Group A: TMJ arthrocentesis alone</td><td align="center" valign="top" rowspan="1" colspan="1">BPI pain, mouth opening, painful/pain&#x02010;free jaw movement, IL&#x02010;6 levels</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pain reduction: Group B had significantly lower pain at weeks 4, 6, and 12 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p>
<p>Mouth opening: Group B showed greater improvement (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p>
<p>IL&#x02010;6 levels: Significant reduction in both groups, no difference between groups.</p>
<p>Adverse effects: None of the group B individuals reported any adverse effects.</p>
<p>Follow&#x02010;up: Baseline, days 1, 5, 7, weeks 4, 6, and 12</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vinuthna et&#x000a0;al. [<xref rid="joor13971-bib-0027" ref-type="bibr">27</xref>] 2020/United Kingdom/Eur J Molecular and Clin Med</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Population: Patients with TMJ pain diagnosed using RDC/TMD criteria, with pain duration &#x02265;&#x02009;3&#x02009;months.</p>
<p>Sample size: 40 (Group I: 20, Group II: 20)</p>
<p>Age (range or mean): &#x02265;&#x02009;18&#x02009;years of age</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">TMJ confirmed by RDC/TMD</td><td align="center" valign="top" rowspan="1" colspan="1">Group II: TMJ arthrocentesis + duloxetine 30&#x02009;mg BID for 12&#x02009;weeks</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Arthrocentesis alone</td><td align="center" valign="top" rowspan="1" colspan="1">VAS for pain, mouth opening (mm)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pain reduction: Group II had significantly lower pain (VAS) at weeks 6 and 12 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p>
<p>Mouth opening: Group II showed significantly greater improvement in maximum mouth opening at weeks 6 and 12 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p>
<p>Adverse effects: None reported.</p>
<p>Follow&#x02010;up: Days 1, 5, 7, weeks 4, 6 and 12</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tak et&#x000a0;al. [<xref rid="joor13971-bib-0028" ref-type="bibr">28</xref>] 2021/India/J Indian Acad Oral Med and Radiol</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Population: Patients aged 18&#x02013;45 with TMD&#x02010;related myalgia or myofascial pain lasting &#x02265;&#x02009;3&#x02009;months, excluding systemic diseases, pregnancy, and medication intolerance</p>
<p>Sample size: 40 (Group I: 20, Group II: 20)</p>
<p>Age (range or mean): Group I: 19&#x02013;44&#x02009;years; Group II: 18&#x02013;45&#x02009;years</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">TMD confirmed by RDC/TMD criteria</td><td align="center" valign="top" rowspan="1" colspan="1">Group II: Gabapentin 100&#x02009;mg BID + Nortriptyline 10&#x02009;mg for 3&#x02009;weeks</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Gabapentin alone 100&#x02009;mg BID for 3&#x02009;weeks</td><td align="center" valign="top" rowspan="1" colspan="1">VAS for pain, maximum interincisal mouth opening, and muscle tenderness sites</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pain reduction: VAS scores decreased significantly more in Group II (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 at week 3).</p>
<p>Mouth opening: Group II showed significantly greater improvement by week 3 (41.5&#x02009;mm vs. 38.35&#x02009;mm; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.003).</p>
<p>Muscle tenderness: Greater reduction in tender sites in Group II (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.008)</p>
<p>Adverse effects: None reported</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ferreira et&#x000a0;al. [<xref rid="joor13971-bib-0029" ref-type="bibr">29</xref>] 2023/Brazil/J Oral Rehabil</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Population: Patients aged &#x02265;&#x02009;18 with painful TMD (arthralgia, myalgia, or TMD headache) for &#x02265;&#x02009;3&#x02009;months, excluding uncontrolled systemic disorders, medication allergies, pregnancy, and recent TMD treatment.</p>
<p>Sample size: 80 (SM&#x02010;duloxetine: 40, SM&#x02010;placebo: 40)</p>
<p>Age (range or mean): SM&#x02010;duloxetine: 38.8&#x02009;&#x000b1;&#x02009;10.6&#x02009;years; SM&#x02010;placebo: 39.7&#x02009;&#x000b1;&#x02009;11.2&#x02009;years</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">TMD confirmed by DC/TMD</td><td align="center" valign="top" rowspan="1" colspan="1">SM&#x02010;duloxetine 60&#x02009;mg/day (titrated over 2&#x02013;3&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Self&#x02010;management (education, self&#x02010;exercise, thermal modalities, dietary suggestions, parafunctional behaviour awareness)</td><td align="center" valign="top" rowspan="1" colspan="1">Pain intensity (NRS), CPM, physical functioning, emotional factors, and safety</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pain reduction: Pain intensity decreased in both groups but no significant difference between groups (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.82).</p>
<p>CPM: More efficient CPM is associated with greater pain reduction, regardless of the treatment group (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.035).</p>
<p>Adverse effects: Higher in the SM&#x02010;duloxetine group (90% vs. 65%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.014).</p>
<p>Follow&#x02010;up: 12&#x02009;weeks</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sousa et&#x000a0;al. [<xref rid="joor13971-bib-0030" ref-type="bibr">30</xref>] 2024/Portugal/Medicina Cl&#x000ed;nica</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Population: Adults with chronic orofacial pain lasting &#x0003e;&#x02009;6&#x02009;months caused by TMD. Excluded: pregnancy, systemic diseases, adverse reactions to study drugs.</p>
<p>Sample Size: 64 (Control: 22, Citalopram: 21, Amitriptyline: 21)</p>
<p>Age (Range or Mean): Control: 36&#x02009;years; Citalopram: 40&#x02009;years; Amitriptyline: 39&#x02009;years</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Chronic orofacial pain caused by TMD. Specific criteria not specified</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Group 2: 10&#x02009;mg/day of citalopram.</p>
<p>Group 3: 25&#x02009;mg/day of amitriptyline.</p>
<p>Both for 9&#x02009;weeks</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Group 1: Michigan&#x02010;style oral appliance only</td><td align="center" valign="top" rowspan="1" colspan="1">VAS for pain intensity</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pain reduction: Amitriptyline group showed the greatest reduction in VAS scores: 3.3&#x02009;&#x000b1;&#x02009;1.5 at 3&#x02009;weeks, 1.5&#x02009;&#x000b1;&#x02009;1.4 at 6&#x02009;weeks, 0.9&#x02009;&#x000b1;&#x02009;1.3 at 9&#x02009;weeks (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.007 compared to control).</p>
<p>Citalopram group showed improvement but was not significantly different from the control group (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.058).</p>
<p>No significant difference between amitriptyline and citalopram (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.692).</p>
<p>Control group (night splint) VAS scores: 5.9&#x02009;&#x000b1;&#x02009;1.3 at baseline, 3.9&#x02009;&#x000b1;&#x02009;2.1 at 3&#x02009;weeks, 3.4&#x02009;&#x000b1;&#x02009;2.2 at 6&#x02009;weeks, 3.1&#x02009;&#x000b1;&#x02009;2.3 at 9&#x02009;weeks.</p>
<p>Adverse effects:</p>
<p>Amitriptyline group: Mild adverse effects reported (dry mouth), not statistically significant.</p>
<p>Follow&#x02010;up: 9&#x02009;weeks</p>
</td></tr></tbody></table><table-wrap-foot id="joor13971-ntgp-0002"><fn id="joor13971-note-0001"><p>Abbreviations: BID, twice daily; BPI, brief pain inventory; CPM, conditioned pain modulation; NRS, numeric rating scale; SM, self&#x02010;management; VAS, visual analogue scale.</p></fn></table-wrap-foot></table-wrap><p>For the synthesis of results, specific effect measures were chosen based on the type of outcome being analysed. Continuous outcomes, including pain reduction and functional improvement, were analysed using mean differences (MD) or standardised mean differences (SMD), each accompanied by 95% confidence intervals (CIs). When studies presented results in varying formats, such as visual analogue score (VAS) scores reported on different scales (e.g., 10&#x02010;point or 100&#x02010;point scales), these were converted to a standardised 0&#x02013;10 scale to ensure comparability across studies.</p><p>To prepare the data for synthesis, measures were standardised as necessary, and when key summary statistics, such as standard deviations, were not reported, they were imputed using available data or derived from related metrics through established statistical formulas. Efforts to contact study authors to obtain missing data were made but were often unsuccessful.</p></sec><sec id="joor13971-sec-0014"><label>2.8</label><title>Level of Evidence</title><p>The overall certainty of the evidence was assessed using the GRADEpro criteria (Grading of Recommendations Assessment, Development, and Evaluation&#x02010;GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2024). This tool assesses the level of evidence among five outcomes of this systematic review: changes in pain intensity among adults of TMD while using the following antidepressants: nortriptyline, duloxetine, amitriptyline, and citalopram. Studies were evaluated according to their study design, risk of bias, inconsistent results, indirect evidence, and imprecision [<xref rid="joor13971-bib-0031" ref-type="bibr">31</xref>].</p></sec></sec><sec sec-type="results" id="joor13971-sec-0015"><label>3</label><title>Results</title><sec id="joor13971-sec-0016"><label>3.1</label><title>Study Selection</title><p>A total of 1930 records were identified through database and&#x000a0;register searches, including Medline (684), Scopus (538), Web of Science (137), Embase (132) and CINAHL [<xref rid="joor13971-bib-0028" ref-type="bibr">28</xref>], Google&#x000a0;Scholar (200), and Cochrane Library (221). The research team also conducted searches of trial registries (<italic toggle="yes">n</italic>&#x02009;=&#x02009;221) and screened the first 200 results from Google Scholar, which has been shown to significantly overlap with Web of Science&#x000a0;[<xref rid="joor13971-bib-0032" ref-type="bibr">32</xref>]. After the removal of 1211 duplicate records, 719 records were screened. Following title and abstract screening, 701 records were excluded. Full&#x02010;text retrieval was sought for&#x000a0;18 studies. Among the retrieved studies, 11 were excluded for the following reasons: wrong intervention (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3), wrong study design (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3), and wrong patient population due to incorrect age (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) (Appendices, Table&#x000a0;<xref rid="joor13971-supitem-0001" ref-type="supplementary-material">S2</xref>). Ultimately, seven studies met the inclusion criteria and were included in the systematic review. The flow of studies through the selection process is illustrated in the PRISMA diagram (Figure&#x000a0;<xref rid="joor13971-fig-0001" ref-type="fig">1</xref>), which provides a detailed account of the number of records identified, screened, assessed for eligibility, and included in the review.</p><fig position="float" fig-type="FIGURE" id="joor13971-fig-0001"><label>FIGURE 1</label><caption><p>PRISMA TMD and antidepressants flowchart.</p></caption><graphic xlink:href="JOOR-52-923-g003" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="joor13971-sec-0017"><label>3.2</label><title>Study Characteristics</title><p>The studies included in this review encompassed a range of methodologies, patient populations, and interventions aimed&#x000a0;at evaluating the role of antidepressants in managing chronic TMD pain. The studies were conducted across various countries, including India, Brazil, and the United Kingdom, and involved different types of antidepressants, such as duloxetine and amitriptyline. The sample sizes varied, with some&#x000a0;studies involving small cohorts of around 12 participants, while others included up to 80 participants. The study durations and specific outcome measures differed, but all focused on assessing the impact of antidepressants on pain relief and overall patient quality of life in individuals with chronic TMD.</p></sec><sec id="joor13971-sec-0018"><label>3.3</label><title>Risk of Bias Assessment</title><p>Five studies were categorised as presenting a high risk of bias, whereas the other two studies were categorised as presenting a low risk of bias. Overall, the identified risk of bias arose from potential bias in the randomisation process and in the measurement of the outcome. Also, some concerns regarding bias due to deviations from intended interventions and selection of the reported results were identified. Figure&#x000a0;<xref rid="joor13971-fig-0002" ref-type="fig">2</xref> summarises the assessed risk of Bias across the included studies. The certainty of evidence can be found in Table&#x000a0;<xref rid="joor13971-tbl-0003" ref-type="table">3</xref>.</p><fig position="float" fig-type="FIGURE" id="joor13971-fig-0002"><label>FIGURE 2</label><caption><p>RoB assessments for each individual study included in the systematic review were evaluated across all 5 domains of the Cochrane RoB 2 tool, including overall RoB rating.</p></caption><graphic xlink:href="JOOR-52-923-g001" position="anchor" id="jats-graphic-5"/></fig><table-wrap position="float" id="joor13971-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Certainty of evidence assessment.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="7" valign="bottom" rowspan="1">Certainty assessment</th><th align="center" colspan="3" valign="bottom" rowspan="1">Summary of findings</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Participants (studies) follow&#x02010;up</th><th align="center" rowspan="2" valign="bottom" colspan="1">Risk of bias</th><th align="center" rowspan="2" valign="bottom" colspan="1">Inconsistency</th><th align="center" rowspan="2" valign="bottom" colspan="1">Indirectness</th><th align="center" rowspan="2" valign="bottom" colspan="1">Imprecision</th><th align="center" rowspan="2" valign="bottom" colspan="1">Publication bias</th><th align="center" rowspan="2" valign="bottom" colspan="1">Overall certainty of evidence</th><th align="center" colspan="2" valign="bottom" rowspan="1">Study event rates (%)</th><th align="center" rowspan="2" valign="bottom" colspan="1">Impact</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">With placebo</th><th align="center" valign="bottom" rowspan="1" colspan="1">With antidepressants</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="10" valign="top" rowspan="1">Nortriptyline (follow&#x02010;up: 3&#x02009;weeks)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">40 (1 RCT)</td><td align="center" valign="top" rowspan="1" colspan="1">Very serious<xref rid="joor13971-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">None</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>&#x02a01;&#x02a01;&#x025ef;&#x025ef;</p>
<p>Low<xref rid="joor13971-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</p>
</td><td align="center" colspan="3" valign="top" rowspan="1">The use of Nortriptyline 10&#x02009;mg, combined to Gabapentin 100&#x02009;mg twice daily, might reduce pain and improve comfortable mouth opening in adults when compared to the use of Gabapentin 100&#x02009;mg twice daily. However, due to the low certainty of evidence, the true effect might be markedly different</td></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">Duloxetine (follow&#x02010;up: 12&#x02009;weeks)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">114 (3 RCTs)</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="joor13971-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="joor13971-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">None</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>&#x02a01;&#x02a01;&#x025ef;&#x025ef;</p>
<p>Low<xref rid="joor13971-note-0003" ref-type="table-fn">
<sup>
a
</sup>
</xref>, <xref rid="joor13971-note-0006" ref-type="table-fn">
<sup>
d
</sup>
</xref>
</p>
</td><td align="center" colspan="3" valign="top" rowspan="1">Contrasting results were observed across studies. The use of 60&#x02009;mg of duloxetine has not shown significant changes in pain intensity when compared to a placebo in one study. In the other two studies, 30&#x02009;mg of duloxetine (twice daily) when combined with arthrocentesis showed a reduction in pain intensity when compared to arthrocentesis only. Also, due to the low certainty of evidence, the true effect might be markedly different. It is not possible to make a recommendation regarding the clinical effectiveness of duloxetine for pain management among adults with TMD pain</td></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">Amitriptyline (follow&#x02010;up: range 2&#x02009;weeks to 12&#x02009;weeks)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">61 (3 RCTs)</td><td align="center" valign="top" rowspan="1" colspan="1">Very serious<xref rid="joor13971-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="joor13971-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">None</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>&#x02a01;&#x025ef;&#x025ef;&#x025ef;</p>
<p>Very low<xref rid="joor13971-note-0004" ref-type="table-fn">
<sup>
b
</sup>
</xref>, <xref rid="joor13971-note-0005" ref-type="table-fn">
<sup>
c
</sup>
</xref>
</p>
</td><td align="center" colspan="3" valign="top" rowspan="1">The use of Amitriptyline 25&#x02009;mg/day showed a significant reduction in pain and discomfort among adults with TMD. However, due to the low certainty of evidence, the true effect is probably markedly different</td></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">Citalopram (follow&#x02010;up: 9&#x02009;weeks)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">42 (1 RCT)</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="joor13971-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="joor13971-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">None</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>&#x02a01;&#x02a01;&#x025ef;&#x025ef;</p>
<p>Low<xref rid="joor13971-note-0003" ref-type="table-fn">
<sup>
a
</sup>
</xref>, <xref rid="joor13971-note-0004" ref-type="table-fn">
<sup>
b
</sup>
</xref>
</p>
</td><td align="center" colspan="3" valign="top" rowspan="1">The use of citalopram 10&#x02009;mg has not shown significant changes in pain intensity when compared to a control group that used a Michigan&#x02010;type nighttime occlusal oral appliance. However, due to the identified low certainty of evidence, the true effect might be markedly different</td></tr></tbody></table><table-wrap-foot id="joor13971-ntgp-0003"><fn id="joor13971-note-0002"><p>Abbreviation: CI, confidence interval.</p></fn><fn id="joor13971-note-0003"><label>
<sup>a</sup>
</label><p>High risk of bias in measurement of the outcome.</p></fn><fn id="joor13971-note-0004"><label>
<sup>b</sup>
</label><p>A substantial variation in 95% CI (&#x0003e;&#x02009;20%) was detected between intervention groups.</p></fn><fn id="joor13971-note-0005"><label>
<sup>c</sup>
</label><p>High risk of bias arising from the randomisation process and in the measurement of the outcome.</p></fn><fn id="joor13971-note-0006"><label>
<sup>d</sup>
</label><p>A substantial variation in 95% CI (&#x0003e;&#x02009;20%) was observed between treatment groups in two studies.</p></fn></table-wrap-foot></table-wrap></sec><sec id="joor13971-sec-0019"><label>3.4</label><title>Synthesis of Results</title><p>The findings from the included studies suggest that antidepressants may play a beneficial role in managing chronic TMD pain, mainly when used in combination with other therapeutic interventions. Several studies demonstrated that integrating antidepressants with non&#x02010;pharmacological approaches, such as trigger point injections or arthrocentesis, enhanced pain relief and improved functional outcomes.</p><p>For instance, duloxetine, a SNRI, enhanced pain relief and functional outcomes when added to arthrocentesis, compared to arthrocentesis alone. These findings highlight the potential for synergistic effects between pharmacological and non&#x02010;pharmacological strategies [<xref rid="joor13971-bib-0010" ref-type="bibr">10</xref>].</p><p>While combination therapies generally yielded better results, the effectiveness of antidepressants as standalone treatments was more variable. Amitriptyline consistently showed significant reductions in pain intensity and improved quality of life, particularly when combined with oral appliances [<xref rid="joor13971-bib-0026" ref-type="bibr">26</xref>, <xref rid="joor13971-bib-0030" ref-type="bibr">30</xref>]. However, the evidence for citalopram was weaker, with studies reporting no significant differences in pain outcomes compared to control treatments, such as oral appliances [<xref rid="joor13971-bib-0030" ref-type="bibr">30</xref>].</p><p>The combination of nortriptyline with gabapentin also showed promising results. Tak et&#x000a0;al. [<xref rid="joor13971-bib-0028" ref-type="bibr">28</xref>] reported that the combination significantly reduced VAS scores compared to gabapentin alone (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001), alongside improved mouth opening and reduced muscle tenderness (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). These findings highlight the potential for antidepressants to enhance outcomes when integrated into multimodal treatment plans.</p><p>Despite these promising results, antidepressants are not without limitations. Side effects, such as those associated with duloxetine (GI disturbances, elevated blood pressure, and drowsiness), were more prevalent in some studies, with higher rates of adverse events reported when compared to placebo or standalone therapies [<xref rid="joor13971-bib-0029" ref-type="bibr">29</xref>]. These findings emphasise the importance of tailoring treatment plans to individual patient needs, weighing potential benefits against the risk of adverse effects.</p><p>The variability in outcomes across studies may also be influenced by differences in study design, populations, and intervention protocols. While some studies reported significant benefits, others highlighted limitations, such as small sample sizes, short follow&#x02010;up periods, and inconsistencies in diagnostic criteria.</p><p>These findings are summarised in Table&#x000a0;<xref rid="joor13971-tbl-0002" ref-type="table">2</xref>, which provides an overview of the included studies, detailing interventions, outcomes, and key results. Overall, the evidence suggests that antidepressants, particularly when used as part of combination therapy, can improve pain management and quality of life for patients with chronic TMD pain. However, further high&#x02010;quality research is needed to establish their standalone efficacy and to refine treatment protocols.</p></sec><sec id="joor13971-sec-0020"><label>3.5</label><title>Heterogeneity Among Studies</title><p>Significant heterogeneity was observed across studies, primarily due to variations in antidepressant types, intervention protocols (e.g., standalone vs. combination treatments), outcome measures (e.g., VAS, mouth opening), and follow&#x02010;up durations (ranging from 2 to 12&#x02009;weeks). These differences limited the ability to compare results directly or perform a quantitative synthesis.</p></sec><sec id="joor13971-sec-0021"><label>3.6</label><title>Certainty of Evidence</title><p>The certainty of the evidence regarding the effect of antidepressants on pain intensity among adults with TMD was graded as very low to amitriptyline 25&#x02009;mg and low to nortriptyline 10&#x02009;mg, duloxetine 60&#x02009;mg, and citalopram 10&#x02009;mg. These results were mainly influenced by the high risk of bias and serious imprecision identified in some studies (Table&#x000a0;<xref rid="joor13971-tbl-0002" ref-type="table">2</xref>).</p></sec></sec><sec sec-type="discussion" id="joor13971-sec-0022"><label>4</label><title>Discussion</title><p>This systematic review evaluated the efficacy of antidepressants in managing chronic TMD pain. To the best of our knowledge, this is the first systematic review to evaluate the efficacy of antidepressants in the management of chronic TMD pain. Antidepressants, such as amitriptyline, duloxetine, and nortriptyline, demonstrated some effectiveness for pain reduction, particularly when used in combination with other therapies like trigger point injections, oral appliances, or arthrocentesis. For example, duloxetine paired with arthrocentesis consistently yielded superior pain relief and functional improvements compared to arthrocentesis alone. Amitriptyline and nortriptyline also showed promising results in improving both pain and functional outcomes across multiple studies. However, the effectiveness of antidepressants as standalone treatments was less consistent, with citalopram showing limited efficacy, which is consistent with other studies showing limited efficacy for selective serotonin reuptake inhibitors (SSRIs) for chronic pain [<xref rid="joor13971-bib-0033" ref-type="bibr">33</xref>, <xref rid="joor13971-bib-0034" ref-type="bibr">34</xref>]. These findings highlight the potential role of antidepressants as an adjunctive treatment for chronic TMD pain.</p><p>The findings of this review align with previous evidence supporting the use of antidepressants for chronic pain management beyond their traditional role in treating mood disorders. For example, Birkinshaw et&#x000a0;al. [<xref rid="joor13971-bib-0033" ref-type="bibr">33</xref>] demonstrated that duloxetine effectively reduced chronic pain across various conditions, consistent with this review's findings of duloxetine providing modest pain relief in TMD&#x02010;related pain. Similarly, McQuay et&#x000a0;al. [<xref rid="joor13971-bib-0035" ref-type="bibr">35</xref>] highlighted the efficacy of low&#x02010;dose amitriptyline (25&#x02009;mg) in significantly reducing chronic nonmalignant pain, aligning with this review's results indicating amitriptyline's role in TMD pain relief. Combination treatments, such as pairing antidepressants with arthrocentesis or oral appliances, generally led to better outcomes than antidepressants alone. Most of the studies reviewed incorporated both pharmacological and non&#x02010;pharmacological approaches, reinforcing the reality that TMD is not solely a physical condition. These findings align with the biopsychosocial model of TMD management, highlighting the importance of addressing psychological and behavioural factors alongside physical treatments to achieve meaningful improvements.</p><p>Other literature further supports these conclusions. Ferreira et&#x000a0;al. [<xref rid="joor13971-bib-0036" ref-type="bibr">36</xref>] found that SNRIs and TCAs had modest effects on chronic pain, including back pain and osteoarthritis, though these effects were not always clinically meaningful, echoing this review's findings on variable efficacy across studies. Kuijpers et&#x000a0;al. [<xref rid="joor13971-bib-0037" ref-type="bibr">37</xref>] similarly reported limited evidence for antidepressants in managing chronic low back pain, citing no significant differences between antidepressants and placebo in many cases, paralleling some inconsistencies noted in TMD pain management. Ferreira et&#x000a0;al. [<xref rid="joor13971-bib-0036" ref-type="bibr">36</xref>] emphasised a significant incidence of adverse effects with SNRIs, such as duloxetine, which corresponds with this review's observation of a relatively higher rate of adverse effects in the duloxetine&#x02010;treated groups.</p><p>Additionally, Goyal et&#x000a0;al. [<xref rid="joor13971-bib-0038" ref-type="bibr">38</xref>] suggested that combination therapies involving antidepressants enhance pain relief, though their non&#x02010;RCT design limits reliability. This aligns with findings in this review where combination approaches, such as duloxetine with arthrocentesis or nortriptyline with gabapentin, showed better outcomes than standalone antidepressant use. The consistent efficacy of antidepressants like duloxetine and amitriptyline in conditions such as fibromyalgia and diabetic neuropathy further reinforces their observed benefits in TMD&#x02010;related pain within this review.</p><p>This alignment highlights the broader applicability of antidepressants in chronic pain management while underscoring the need for high&#x02010;quality, long&#x02010;term research to address the observed heterogeneity and methodological limitations.</p><sec id="joor13971-sec-0023"><label>4.1</label><title>Clinical Implications</title><p>The findings of this review underscore the potential for antidepressants to expand the therapeutic toolkit for managing chronic TMD pain. These medications offer an evidence&#x02010;based, non&#x02010;invasive treatment option for patients who are either not candidates for surgical interventions or prefer less invasive approaches. Additionally, pairing antidepressants with other therapies may maximise treatment outcomes. Clinicians should consider integrating these options into multimodal treatment plans while discussing the risks and benefits with patients.</p><p>This review highlights the importance of tailoring treatment approaches to individual patient needs, as certain antidepressants demonstrated higher incidences of adverse effects. For instance, duloxetine was associated with more frequent side effects compared to placebo, including nausea, dry mouth, fatigue, insomnia, and increased sweating, emphasising the need for careful patient selection and monitoring. The results advocate for the inclusion of antidepressants as adjunctive therapies, potentially improving the quality of life for TMD patients.</p></sec><sec id="joor13971-sec-0024"><label>4.2</label><title>Strengths and Limitations</title><p>This systematic review has several notable strengths. First, it adhered to PRISMA guidelines, ensuring a transparent and methodologically robust process for study selection, data extraction, and synthesis. The inclusion of a diverse range of antidepressants, study designs, and therapeutic approaches provides a comprehensive overview of the potential role of antidepressants in managing chronic TMD pain. Additionally, the use of the Cochrane Risk of Bias 2 tool enabled a rigorous assessment of methodological quality, enhancing the reliability of the findings.</p><p>However, there are important limitations to consider. The review included only seven high&#x02010;quality RCTs, all of which had fairly small sample sizes, with the largest including 80 patients. Five of these studies exhibited a high risk of bias. One study had a particularly small sample size of only 12 participants, which limits the generalisability and statistical power of its findings. Furthermore, approximately 20 potentially relevant studies were excluded due to lack of access, introducing the potential for selection bias. The studies included in the review also demonstrated considerable heterogeneity in terms of interventions, outcome measures, and follow&#x02010;up durations. For example, not all studies used standardised pain scales, such as the VAS, which precluded a meta&#x02010;analysis. Other factors that prevented conducting a meta&#x02010;analysis include variations in the interventions used across the studies and inconsistencies in how the data was reported. Most studies also had short intervention and follow&#x02010;up durations, failing to account for the long&#x02010;term efficacy and safety of antidepressant use in this population. Due to the variability among the included studies, we were unable to assess the effectiveness of antidepressants separately for patients with myogenous versus arthrogenous TMD. Recognising this distinction is essential for future research and could help refine treatment approaches.</p><p>A further limitation relates to the review process itself. The search strategy excluded grey literature and non&#x02010;English language studies, which may have increased the risk of publication bias. While two reviewers independently screened studies, subjective bias in study selection and data extraction cannot be entirely ruled out. Additionally, data extraction was hindered by incomplete reporting in some studies, and efforts to contact authors for clarification were often unsuccessful. The inability to conduct a meta&#x02010;analysis due to heterogeneity restricted the ability to provide pooled effect estimates, and while a narrative approach was used to assess the certainty of evidence, formal frameworks were not consistently applied.</p><p>Finally, several included studies were assessed as having a high risk of bias due to issues such as inadequate randomisation, lack of blinding, or incomplete outcome data. These methodological shortcomings reduce the certainty of the evidence and highlight the need for more rigorous study designs in future research. Despite these limitations, the review provides valuable insights into the potential role of antidepressants in chronic TMD pain management and underscores the need for high&#x02010;quality, standardised studies to better inform clinical practice.</p></sec><sec id="joor13971-sec-0025"><label>4.3</label><title>Future Directions</title><p>Future research should address the gaps identified in this review to clarify the role of antidepressants in chronic TMD pain management. Comparative studies evaluating different antidepressant classes, optimal dosing, treatment duration, and long&#x02010;term safety are needed. Standardised outcome measures, such as VAS or NRS, should be adopted to facilitate comparisons and meta&#x02010;analyses. Investigating patient&#x02010;centered outcomes, genetic factors, and predictors of response may support more personalised treatment approaches.</p><p>Further research should also focus on determining the optimal timing for introducing antidepressants in TMD management. Understanding when these medications provide the most benefit&#x02014;whether as an early intervention in patients with central sensitisation features or as a later option for those unresponsive to conservative care&#x02014;could help refine treatment protocols. Establishing clear clinical guidelines for incorporating antidepressants may not only improve pain and function but also reduce the need for more invasive treatments by effectively addressing central pain mechanisms before symptoms become refractory.</p></sec></sec><sec sec-type="conclusions" id="joor13971-sec-0026"><label>5</label><title>Conclusions</title><p>This systematic review suggests that antidepressants may reduce pain and improve function in chronic TMD patients, particularly when combined with other treatments. Medications such as TCAs and duloxetine showed potential benefits. However, the evidence remains limited by small sample sizes, short follow&#x02010;up periods, and study heterogeneity. Future research should refine dosing, evaluate long&#x02010;term safety, focus on patient&#x02010;centered outcomes, and assess the role of comorbidities to guide clinical practice. Until more robust evidence is available, antidepressants should be integrated into a personalised, multimodal treatment approach rather than used as a standalone therapy.</p></sec><sec id="joor13971-sec-0031"><title>Author Contributions</title><p>
<bold>Takara Dei:</bold> conceptualisation, methodology, data curation, formal analysis, writing &#x02013; original draft, writing &#x02013; review and editing. <bold>Kennedy Galloway:</bold> data curation, screening and study selection, writing &#x02013; original draft, writing &#x02013; review an editing. <bold>Nathalia Carolina Fernandes Fagundes:</bold> formal analysis, writing &#x02013; review and editing. <bold>Janice Y. Kung:</bold> search strategy development, literature search execution, data curation, writing &#x02013; review and editing. <bold>Nathan P. Beahm:</bold> writing &#x02013; original draft, writing &#x02013; review and editing. <bold>Reid Friesen:</bold> conceptualisation, supervision, methodology, data analysis, writing &#x02013; original draft, writing &#x02013; review and editing, project administration. All authors reviewed and approved the final manuscript and agree to be accountable for all aspects of the work, ensuring its accuracy and integrity.</p></sec><sec sec-type="COI-statement" id="joor13971-sec-0028"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="joor13971-sec-0029"><sec disp-level="2" id="joor13971-sec-0032"><title>Peer Review</title><p>The peer review history for this article is available at <ext-link xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/joor.13971" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer&#x02010;review/10.1111/joor.13971</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="joor13971-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="JOOR-52-923-s001.docx"/></supplementary-material></sec></body><back><ack id="joor13971-sec-0027"><title>Acknowledgements</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="joor13971-sec-0030"><title>Data Availability Statement</title><p>The following materials used in this systematic review are available upon request: template data collection forms, extracted data from included studies, data used for analyses, and analytic code. These materials are not publicly posted but can be obtained by contacting the corresponding author, Dr. Reid Friesen, at <email>rtfriese@ualberta.ca</email>.</p></sec><ref-list content-type="cited-references" id="joor13971-bibl-0001"><title>References</title><ref id="joor13971-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="joor13971-cit-0001">
<string-name>
<given-names>T.</given-names>
<surname>List</surname>
</string-name> and <string-name>
<given-names>R. H.</given-names>
<surname>Jensen</surname>
</string-name>, &#x0201c;<article-title>Temporomandibular Disorders: Old Ideas and New Concepts</article-title>,&#x0201d; <source>Cephalalgia</source>
<volume>37</volume>, no. <issue>7</issue> (<year>2017</year>): <fpage>692</fpage>&#x02013;<lpage>704</lpage>, <pub-id pub-id-type="doi">10.1177/0333102416686302</pub-id>.<pub-id pub-id-type="pmid">28068790</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="joor13971-cit-0002">
<string-name>
<given-names>E. M.</given-names>
<surname>Matheson</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Fermo</surname>
</string-name>, and <string-name>
<given-names>R. S.</given-names>
<surname>Blackwelder</surname>
</string-name>, &#x0201c;<article-title>Temporomandibular Disorders: Rapid Evidence Review</article-title>,&#x0201d; <source>American Family Physician</source>
<volume>107</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>52</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">36689971</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="joor13971-cit-0003">
<string-name>
<given-names>R. G.</given-names>
<surname>Hoffmann</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Kotchen</surname>
</string-name>, <string-name>
<given-names>T. A.</given-names>
<surname>Kotchen</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Cowley</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Dasgupta</surname>
</string-name>, and <string-name>
<given-names>A. W.</given-names>
<surname>Cowley</surname>, <suffix>Jr.</suffix>
</string-name>, &#x0201c;<article-title>Temporomandibular Disorders and Associated Clinical Comorbidities</article-title>,&#x0201d; <source>Clinical Journal of Pain</source>
<volume>27</volume>, no. <issue>3</issue> (<year>2011</year>): <fpage>268</fpage>&#x02013;<lpage>274</lpage>, <pub-id pub-id-type="doi">10.1097/AJP.0b013e31820215f5</pub-id>.<pub-id pub-id-type="pmid">21178593</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="joor13971-cit-0004">
<string-name>
<given-names>R. B.</given-names>
<surname>Fillingim</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ohrbach</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Greenspan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Psychological Factors Associated With Development of TMD: The OPPERA Prospective Cohort Study</article-title>,&#x0201d; <source>Journal of Pain</source>
<volume>14</volume>, no. <issue>12</issue> (<year>2013</year>): <fpage>75</fpage>&#x02013;<lpage>90</lpage>, <pub-id pub-id-type="doi">10.1016/j.jpain.2013.06.009</pub-id>.</mixed-citation></ref><ref id="joor13971-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="joor13971-cit-0005">
<string-name>
<given-names>C. M.</given-names>
<surname>Kaplan</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Kelleher</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Irani</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Schrepf</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Clauw</surname>
</string-name>, and <string-name>
<given-names>S. E.</given-names>
<surname>Harte</surname>
</string-name>, &#x0201c;<article-title>Deciphering Nociplastic Pain: Clinical Features, Risk Factors and Potential Mechanisms</article-title>,&#x0201d; <source>Nature Reviews. Neurology</source>
<volume>20</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>347</fpage>&#x02013;<lpage>363</lpage>, <pub-id pub-id-type="doi">10.1038/s41582-024-00966-8</pub-id>.<pub-id pub-id-type="pmid">38755449</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="joor13971-cit-0006">
<string-name>
<given-names>P.</given-names>
<surname>Svensson</surname>
</string-name>, &#x0201c;<article-title>Could Painful Temporomandibular Disorders Be Nociplastic in Nature? A Critical Review and New Proposal</article-title>,&#x0201d; <source>Acta Odontologica Scandinavica</source>
<volume>83</volume> (<year>2024</year>): <fpage>144</fpage>&#x02013;<lpage>150</lpage>, <pub-id pub-id-type="doi">10.2340/aos.v83.40586</pub-id>.<pub-id pub-id-type="pmid">38623025</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="joor13971-cit-0007">
<string-name>
<given-names>S. A.</given-names>
<surname>Al&#x02010;hadad</surname>
</string-name>, <string-name>
<given-names>M. M. S.</given-names>
<surname>Ahmed</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Skeletal, Dentoalveolar and Soft Tissue Changes After Stabilization Splint Treatment for Patients With Temporomandibular Joint Disorders</article-title>,&#x0201d; <source>BMC Oral Health</source>
<volume>24</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>479</fpage>, <pub-id pub-id-type="doi">10.1186/s12903-024-04260-3</pub-id>.<pub-id pub-id-type="pmid">38643111</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="joor13971-cit-0008">
<string-name>
<given-names>G.</given-names>
<surname>Dimitroulis</surname>
</string-name>, &#x0201c;<article-title>Management of Temporomandibular Joint Disorders: A Surgeon's Perspective</article-title>,&#x0201d; <source>Australian Dental Journal</source>
<volume>63</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>S79</fpage>&#x02013;<lpage>S90</lpage>, <pub-id pub-id-type="doi">10.1111/adj.12593</pub-id>.<pub-id pub-id-type="pmid">29574810</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0009"><label>9</label><mixed-citation publication-type="book" id="joor13971-cit-0009">
<string-name>
<given-names>Z. M.</given-names>
<surname>Sheffler</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Patel</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Abdijadid</surname>
</string-name>, &#x0201c;<part-title>Antidepressants</part-title>,&#x0201d; in <source>In: StatPearls</source> (<publisher-name>StatPearls Publishing</publisher-name>, <year>2024</year>).</mixed-citation></ref><ref id="joor13971-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="joor13971-cit-0010">
<string-name>
<given-names>R. K.</given-names>
<surname>Singh</surname>
</string-name>, <string-name>
<given-names>U. S.</given-names>
<surname>Pal</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Goyal</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Nischal</surname>
</string-name>, <string-name>
<given-names>T. R.</given-names>
<surname>Gurung</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Daga</surname>
</string-name>, &#x0201c;<article-title>TMJ Arthrocentesis Alone and in Combination With Duloxetine in Temporomandibular Joint Pain</article-title>,&#x0201d; <source>Journal of Oral and Maxillofacial Surgery</source>
<volume>17</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>270</fpage>&#x02013;<lpage>275</lpage>, <pub-id pub-id-type="doi">10.1007/s12663-017-1037-4</pub-id>.</mixed-citation></ref><ref id="joor13971-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="joor13971-cit-0011">
<string-name>
<given-names>R. A.</given-names>
<surname>Sansone</surname>
</string-name> and <string-name>
<given-names>L. A.</given-names>
<surname>Sansone</surname>
</string-name>, &#x0201c;<article-title>Pain, Pain, Go Away: Antidepressants and Pain Management</article-title>,&#x0201d; <source>Psychiatry (Edgmont)</source>
<volume>5</volume>, no. <issue>12</issue> (<year>2008</year>): <fpage>16</fpage>&#x02013;<lpage>19</lpage>.</mixed-citation></ref><ref id="joor13971-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="joor13971-cit-0012">
<collab collab-type="authors">Cleveland Clinic</collab>
, <article-title>&#x0201c;Tricyclic Antidepressants,&#x0201d;</article-title> accessed September 19, 2024, <ext-link xlink:href="https://my.clevelandclinic.org/health/treatments/25146-tricyclic-antidepressants" ext-link-type="uri">https://my.clevelandclinic.org/health/treatments/25146&#x02010;tricyclic&#x02010;antidepressants</ext-link>.</mixed-citation></ref><ref id="joor13971-bib-0013"><label>13</label><mixed-citation publication-type="book" id="joor13971-cit-0013">
<string-name>
<given-names>J.</given-names>
<surname>Moraczewski</surname>
</string-name>, <string-name>
<given-names>A. O.</given-names>
<surname>Awosika</surname>
</string-name>, and <string-name>
<given-names>K. K.</given-names>
<surname>Aedma</surname>
</string-name>, &#x0201c;<part-title>Tricyclic Antidepressants</part-title>,&#x0201d; in <source>StatPearls</source> (<publisher-name>StatPearls Publishing</publisher-name>, <year>2024</year>).</mixed-citation></ref><ref id="joor13971-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="joor13971-cit-0014">
<collab collab-type="authors">SSRIs</collab>
, <article-title>&#x0201c;Cleveland Clinic,&#x0201d;</article-title> accessed December 8, 2024, <ext-link xlink:href="https://my.clevelandclinic.org/health/treatments/24795-ssri" ext-link-type="uri">https://my.clevelandclinic.org/health/treatments/24795&#x02010;ssri</ext-link>.</mixed-citation></ref><ref id="joor13971-bib-0015"><label>15</label><mixed-citation publication-type="book" id="joor13971-cit-0015">
<string-name>
<given-names>A.</given-names>
<surname>Chu</surname>
</string-name> and <string-name>
<given-names>R.</given-names>
<surname>Wadhwa</surname>
</string-name>, &#x0201c;<part-title>Selective Serotonin Reuptake Inhibitors</part-title>,&#x0201d; in <source>StatPearls</source> (<publisher-name>StatPearls Publishing</publisher-name>, <year>2024</year>), <ext-link xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK554406/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/books/NBK554406/</ext-link>.</mixed-citation></ref><ref id="joor13971-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="joor13971-cit-0016">
<collab collab-type="authors">U.S. Food and Drug Administration (FDA)</collab>
, <article-title>&#x0201c;Cymbalta (Duloxetine Delayed&#x02010;Release Capsules): Label Information,&#x0201d;</article-title>
<year>2020</year>, <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021427s052lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021427s052lbl.pdf</ext-link>.</mixed-citation></ref><ref id="joor13971-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="joor13971-cit-0017">
<string-name>
<given-names>D.</given-names>
<surname>Fanelli</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Weller</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Liu</surname>
</string-name>, &#x0201c;<article-title>New Serotonin&#x02010;Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations</article-title>,&#x0201d; <source>Neurology International</source>
<volume>13</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>497</fpage>&#x02013;<lpage>509</lpage>, <pub-id pub-id-type="doi">10.3390/neurolint13040049</pub-id>.<pub-id pub-id-type="pmid">34698218</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="joor13971-cit-0018">
<string-name>
<given-names>C.</given-names>
<surname>Robinson</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Dalal</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Chitneni</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain</article-title>,&#x0201d; <source>Health Psychology Research</source>
<volume>10</volume>, no. <issue>2</issue> (<year>2022</year>): <elocation-id>32309</elocation-id>, <pub-id pub-id-type="doi">10.52965/001c.32309</pub-id>.<pub-id pub-id-type="pmid">35774919</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="joor13971-cit-0019">
<string-name>
<given-names>G.</given-names>
<surname>Noe</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Shah</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ongchuan</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Munjal</surname>
</string-name>, &#x0201c;<article-title>Clinical Presentations of Bupropion Prescription Drug Misuse: A Systematic Review</article-title>,&#x0201d; <source>Journal of Clinical Psychopharmacology</source>
<volume>44</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>284</fpage>&#x02013;<lpage>290</lpage>, <pub-id pub-id-type="doi">10.1097/JCP.0000000000001858</pub-id>.<pub-id pub-id-type="pmid">38656298</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="joor13971-cit-0020">
<string-name>
<given-names>T. M.</given-names>
<surname>Hillhouse</surname>
</string-name> and <string-name>
<given-names>J. H.</given-names>
<surname>Porter</surname>
</string-name>, &#x0201c;<article-title>A Brief History of the Development of Antidepressant Drugs: From Monoamines to Glutamate</article-title>,&#x0201d; <source>Experimental and Clinical Psychopharmacology</source>
<volume>23</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>1</fpage>&#x02013;<lpage>21</lpage>, <pub-id pub-id-type="doi">10.1037/a0038550</pub-id>.<pub-id pub-id-type="pmid">25643025</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0021"><label>21</label><mixed-citation publication-type="book" id="joor13971-cit-0021">
<string-name>
<given-names>T.</given-names>
<surname>Sub Laban</surname>
</string-name> and <string-name>
<given-names>A.</given-names>
<surname>Saadabadi</surname>
</string-name>, &#x0201c;<part-title>Monoamine Oxidase Inhibitors</part-title>,&#x0201d; in <source>StatPearls</source> (<publisher-name>StatPearls Publishing</publisher-name>, <year>2024</year>), <ext-link xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK539848/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/books/NBK539848/</ext-link>.</mixed-citation></ref><ref id="joor13971-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="joor13971-cit-0022">
<string-name>
<given-names>C.</given-names>
<surname>Crapanzano</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Casolaro</surname>
</string-name>, and <string-name>
<given-names>A. J.</given-names>
<surname>Krupa</surname>
</string-name>, &#x0201c;<article-title>Clinical Experience With Parenteral Trazodone in Mood Disorders: A Literature Review</article-title>,&#x0201d; <source>Psychiatria Polska</source>
<volume>58</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>449</fpage>&#x02013;<lpage>466</lpage>, <pub-id pub-id-type="doi">10.12740/PP/182933</pub-id>.<pub-id pub-id-type="pmid">39217422</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="joor13971-cit-0023">
<string-name>
<given-names>M. J.</given-names>
<surname>Page</surname>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>McKenzie</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>Bossuyt</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</article-title>,&#x0201d; <source>BMJ</source>
<volume>29</volume> (<year>2021</year>): <elocation-id>n71</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>.</mixed-citation></ref><ref id="joor13971-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="joor13971-cit-0024">
<string-name>
<given-names>J. A. C.</given-names>
<surname>Sterne</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Savovi&#x00107;</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Page</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials</article-title>,&#x0201d; <source>BMJ</source>
<volume>366</volume> (<year>2019</year>): <elocation-id>l4898</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id>.<pub-id pub-id-type="pmid">31462531</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="joor13971-cit-0025">
<string-name>
<given-names>C. M.</given-names>
<surname>Rizzatti&#x02010;Barbosa</surname>
</string-name>, <string-name>
<given-names>M. T. P.</given-names>
<surname>Nogueira</surname>
</string-name>, <string-name>
<given-names>E. D.</given-names>
<surname>de Andrade</surname>
</string-name>, <string-name>
<given-names>G. M. B.</given-names>
<surname>Ambrosano</surname>
</string-name>, and <string-name>
<given-names>J. R.</given-names>
<surname>de Albergaria Barbosa</surname>
</string-name>, &#x0201c;<article-title>Clinical Evaluation of Amitriptyline for the Control of Chronic Pain Caused by Temporomandibular Joint Disorders</article-title>,&#x0201d; <source>Cranio</source>
<volume>21</volume>, no. <issue>3</issue> (<year>2003</year>): <fpage>221</fpage>&#x02013;<lpage>225</lpage>, <pub-id pub-id-type="doi">10.1080/08869634.2003.11746254</pub-id>.<pub-id pub-id-type="pmid">12889679</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="joor13971-cit-0026">
<string-name>
<given-names>I. Z.</given-names>
<surname>Alajbeg</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Brakus</surname>
</string-name>, <string-name>
<given-names>R. B.</given-names>
<surname>Brakus</surname>
</string-name>, and <string-name>
<given-names>I.</given-names>
<surname>Brakus</surname>
</string-name>, &#x0201c;<article-title>Comparison of Amitriptyline With Stabilization Splint and Placebo in Chronic TMD Patients: A Pilot Study</article-title>,&#x0201d; <source>Acta Stomatologica Croatica</source>
<volume>52</volume>, no. <issue>2</issue> (<year>2018</year>): <fpage>114</fpage>&#x02013;<lpage>122</lpage>, <pub-id pub-id-type="doi">10.15644/asc52/2/4</pub-id>.<pub-id pub-id-type="pmid">30034010</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="joor13971-cit-0027">
<string-name>
<given-names>M.</given-names>
<surname>Vinuthna</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Bhagat</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Afsal</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Kumar</surname>
</string-name>, <string-name>
<given-names>N. S.</given-names>
<surname>Samuel</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Swaroop</surname>
</string-name>, &#x0201c;<article-title>A Comparison of the Efficacy of Arthrocentesis Alone and Arthrocentesis With Duloxetine in Patients With TMJ Pain</article-title>,&#x0201d; <source>European Journal of Molecular and Clinical Medicine</source>
<volume>7</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>7842</fpage>&#x02013;<lpage>7847</lpage>.</mixed-citation></ref><ref id="joor13971-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="joor13971-cit-0028">
<string-name>
<given-names>M. M.</given-names>
<surname>Tak</surname>
</string-name>, <string-name>
<given-names>A. H.</given-names>
<surname>Chalkoo</surname>
</string-name>, <string-name>
<given-names>T. A.</given-names>
<surname>Bhat</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Jan</surname>
</string-name>, &#x0201c;<article-title>Comparative Evaluation of the Efficacy of Gabapentin and Gabapentin in Combination With Nortriptyline in the Management of Pain&#x02010;Related Temporomandibular Disorders</article-title>,&#x0201d; <source>Journal of Indian Academy of Oral Medicine and Radiology</source>
<volume>33</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>171</fpage>&#x02013;<lpage>176</lpage>, <pub-id pub-id-type="doi">10.4103/jiaomr.jiaomr_204_20</pub-id>.</mixed-citation></ref><ref id="joor13971-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="joor13971-cit-0029">
<string-name>
<given-names>G. E.</given-names>
<surname>Ferreira</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Abdel&#x02010;Shaheed</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Underwood</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy, Safety, and Tolerability of Antidepressants for Pain in Adults: Overview of Systematic Reviews</article-title>,&#x0201d; <source>BMJ</source>
<volume>380</volume> (<year>2023</year>): <elocation-id>e072415</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmj-2022-072415</pub-id>.<pub-id pub-id-type="pmid">36725015</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="joor13971-cit-0030">
<string-name>
<given-names>B. M.</given-names>
<surname>de Sousa</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>L&#x000f3;pez&#x02010;Valverde</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Caramelo</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Rodrigues</surname>
</string-name>, and <string-name>
<given-names>N.</given-names>
<surname>L&#x000f3;pez&#x02010;Valverde</surname>
</string-name>, &#x0201c;<article-title>Use of Antidepressants in the Treatment of Chronic Orofacial Pain Caused by Temporomandibular Disorders: A Randomized Controlled Clinical Trial</article-title>,&#x0201d; <source>Medicina Cl&#x000ed;nica (Barcelona)</source>
<volume>163</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>74</fpage>&#x02013;<lpage>77</lpage>, <pub-id pub-id-type="doi">10.1016/j.medcli.2024.02.002</pub-id>.</mixed-citation></ref><ref id="joor13971-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous" id="joor13971-cit-0031">
<string-name>
<given-names>H.</given-names>
<surname>Sch&#x000fc;nemann</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Bro&#x0017c;ek</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Guyatt</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Oxman</surname>
</string-name>, <article-title>&#x0201c;GRADE Handbook: Introduction to GRADE Handbook. Handbook for Grading the Quality of Evidence and the Strengh of Recommendations Using the GRADE Approach,&#x0201d;</article-title>
<year>2013</year>, The GRADE Working Group, <ext-link xlink:href="https://gdt.gradepro.org/app/handbook/handbook.html" ext-link-type="uri">https://gdt.gradepro.org/app/handbook/handbook.html</ext-link>.</mixed-citation></ref><ref id="joor13971-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="joor13971-cit-0032">
<string-name>
<given-names>N. R.</given-names>
<surname>Haddaway</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Collins</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Coughlin</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Kirk</surname>
</string-name>, &#x0201c;<article-title>The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching</article-title>,&#x0201d; <source>PLoS One</source>
<volume>10</volume>, no. <issue>9</issue> (<year>2015</year>): <fpage>1</fpage>&#x02013;<lpage>17</lpage>, <pub-id pub-id-type="doi">10.1371/journal.pone.0138237</pub-id>.</mixed-citation></ref><ref id="joor13971-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="joor13971-cit-0033">
<string-name>
<given-names>H.</given-names>
<surname>Birkinshaw</surname>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Friedrich</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Cole</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Antidepressants for Pain Management in Adults With Chronic Pain: A Network Meta&#x02010;Analysis Cochrane Pain, Palliative and Supportive Care Group</article-title>,&#x0201d; <source>Cochrane Database of Systematic Reviews</source>
<volume>5</volume>, no. <issue>5</issue> (<year>2023</year>): <elocation-id>CD014682</elocation-id>, <pub-id pub-id-type="doi">10.1002/14651858.CD014682.pub2</pub-id>.<pub-id pub-id-type="pmid">37160297</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="joor13971-cit-0034">
<string-name>
<given-names>E.</given-names>
<surname>Patetsos</surname>
</string-name> and <string-name>
<given-names>E.</given-names>
<surname>Horjales&#x02010;Araujo</surname>
</string-name>, &#x0201c;<article-title>Treating Chronic Pain With SSRIs: What Do we Know?</article-title>,&#x0201d; <source>Pain Research &#x00026; Management</source>
<volume>2016</volume> (<year>2016</year>): <elocation-id>2020915</elocation-id>, <pub-id pub-id-type="doi">10.1155/2016/2020915</pub-id>.<pub-id pub-id-type="pmid">27445601</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="joor13971-cit-0035">
<string-name>
<given-names>H. J.</given-names>
<surname>McQuay</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Caroll</surname>
</string-name>, and <string-name>
<given-names>C. J.</given-names>
<surname>Glynn</surname>
</string-name>, &#x0201c;<article-title>Low Dose Amitriptyline in the Treatment of Chronic Pain</article-title>,&#x0201d; <source>Anaesthesia</source>
<volume>47</volume>, no. <issue>8</issue> (<year>1992</year>): <fpage>646</fpage>&#x02013;<lpage>652</lpage>, <pub-id pub-id-type="doi">10.1111/j.1365-2044.1992.tb02383.x</pub-id>.<pub-id pub-id-type="pmid">1519713</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="joor13971-cit-0036">
<string-name>
<given-names>G. E.</given-names>
<surname>Ferreira</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>McLachlan</surname>
</string-name>, <string-name>
<given-names>C. W. C.</given-names>
<surname>Lin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy and Safety of Antidepressants for the Treatment of Back Pain and Osteoarthritis: Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>BMJ</source>
<volume>372</volume> (<year>2021</year>): <elocation-id>m4825</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmj.m4825</pub-id>.<pub-id pub-id-type="pmid">33472813</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="joor13971-cit-0037">
<string-name>
<given-names>T.</given-names>
<surname>Kuijpers</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Middelkoop</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Rubinstein</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Systematic Review on the Effectiveness of Pharmacological Interventions for Chronic Non&#x02010;Specific Low&#x02010;Back Pain</article-title>,&#x0201d; <source>European Spine Journal</source>
<volume>20</volume>, no. <issue>1</issue> (<year>2011</year>): <fpage>40</fpage>&#x02013;<lpage>50</lpage>, <pub-id pub-id-type="doi">10.1007/s00586-010-1541-4</pub-id>.<pub-id pub-id-type="pmid">20680369</pub-id>
</mixed-citation></ref><ref id="joor13971-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="joor13971-cit-0038">
<string-name>
<given-names>P.</given-names>
<surname>Goyal</surname>
</string-name>, <string-name>
<given-names>R. K.</given-names>
<surname>Singh</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Gangwar</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Mohammad</surname>
</string-name>, <string-name>
<given-names>U. S.</given-names>
<surname>Pal</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Singh</surname>
</string-name>, &#x0201c;<article-title>Effect of Duloxetine in Temporomandibular Joint Disorders: A Comparison With Arthrocentesis</article-title>,&#x0201d; <source>National Journal of Maxillofacial Surgery</source>
<volume>11</volume>, no. <issue>2</issue> (<year>2020</year>): <fpage>219</fpage>&#x02013;<lpage>223</lpage>, <pub-id pub-id-type="doi">10.4103/njms.NJMS_86_19</pub-id>.<pub-id pub-id-type="pmid">33897184</pub-id>
</mixed-citation></ref></ref-list></back></article>